Background {#Sec1}
==========

Persons with autism spectrum disorder (ASD) have many physiological abnormalities compared to typically developing children. These abnormalities cluster into four areas: oxidative stress, inflammation/immune dysregulation, mitochondrial dysfunction, and environmental toxicant exposure \[[@CR1]\]. Prior studies examining physiological abnormalities have examined biomarkers for one particular metabolic pathway (such as cytokines \[[@CR2]\], oxidative stress \[[@CR3]\], or mitochondrial dysfunction \[[@CR4]\]), and a variety of others has been proposed \[[@CR5]\]. However, recent studies have used metabolomics---the study of all metabolites present in a cell, organism, tissue, or sample (e.g., blood, urine, saliva, feces)---to more broadly examine differences in multiple, concurrent physiological mechanisms in children with ASD. These metabolomics studies comparing children with ASD to typical controls have identified many physiological abnormalities that also cluster into similar categories of dysfunctional redox status, inflammatory status, and mitochondrial function as well as metabolomic signals that suggest abnormalities in the gut microbiome (the microbial population of an individual's gastrointestinal tract, which is increasingly recognized as an important contributor to health and disease) \[[@CR6]--[@CR16]\]. Together, all of these studies strongly suggest that persons with autism have abnormal physiology that may be intermittent or continuous.

An exciting therapeutic potential in ASD involves the treatment of these identified physiological abnormalities when they are active. Correction of these abnormalities may improve behavior, symptoms, and quality of life in ASD. Preliminary evidence from intervention trials supports this possibility. For instance, children with autism who were treated with the antioxidant *N*-acetylcysteine (NAC) for 12 weeks had significant improvements in irritability compared to children treated with placebo \[[@CR17]\]. In a recent randomized controlled trial of methylcobalamin (methyl B12), children with ASD who were treated with this methyl donor had significant improvements in the Aberrant Behavior Checklist (ABC) compared to those treated with placebo, and improvements were correlated with physiological measures that indicated improved antioxidant status \[[@CR18]\].

A previous, small, randomized controlled trial examined the efficacy of sulforaphane for the treatment of children with ASD \[[@CR19]\]. Sulforaphane is an indirect antioxidant from broccoli sprout and seed extracts \[[@CR20]\]. Sulforaphane has many physiological effects, including upregulation of cytoprotective enzymes and increases in detoxification and excretion of highly reactive and potentially damaging toxicants and free radicals. During the 18-week trial, children receiving oral sulforaphane demonstrated marked improvements in both the ABC and the SRS \[[@CR19]\]. Further, the observed benefits disappeared and returned to baseline when the treatment was stopped. However, the above study did not examine the physiological changes in children with ASD undergoing treatment.

We therefore sought to examine changes in physiological markers that may underlie beneficial treatment effects from sulforaphane by analyzing changes in urinary metabolites. In an open-label clinical trial of 15 school-age children with ASD, we performed metabolomics analyses of urine before and after treatment to determine if there are changes in the low molecular weight products of metabolism associated with treatment response, which might explain the mechanism of action of this phytochemical.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

The study was approved by the Committee on Human Research at the University of California, San Francisco (UCSF) on November 5, 2015, and the trial was registered at [clinicaltrials.gov](http://clinicaltrials.gov) (NCT02654743) on January 11, 2016, prior to performing any study activities. Participants completed the study on May 9, 2016, and metabolomics analyses were completed in September 2016.

Prior to initiating the study, the UCSF investigators developed a relationship with a local, non-public school (Oak Hill School, San Anselmo, CA) that specializes in the education of children and young adults with autism and related neurodevelopmental disorders (ages 5--22, grades K-12). This unique academic-school-parent partnership was created with the goal of improving overall care and communication between caregivers, clinical providers, and teachers. All children/families attending the school (*n* = 35 at study initiation) were invited to participate in the study through e-mail, informational flyers, and an evening informational session.

Children and young adults were eligible to participate if they were enrolled in the school, had a formal diagnosis of autism, reported no prior use of sulforaphane-containing supplements, were willing to hold other treatments constant for the 12-week study period, had no major medical problems other than ASD, were willing to provide urine samples, and parents were willing to complete online surveys at specified intervals. ASD was defined as being present if the child had a diagnosis from a medical professional trained to diagnose autism or if the student was determined by school staff and the study psychiatrist to meet *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition (*DSM--IV*) criteria for ASD. Informed consent was obtained from the parent/caregiver of all study participants.

Intervention {#Sec4}
------------

The study was open-label, and all clinicians, parents, and teachers were aware of the treatment initiation and duration of 12 weeks. All enrolled children were provided weight-based dosing of sulforaphane (\~ 2.5 μmol glucoraphanin (GR)/lb). Avmacol^®^, a sulforaphane-producing dietary supplement, was provided at no cost by Nutramax Laboratories Consumer Care, Inc. (Edgewood, MD). Each tablet provides a proprietary broccoli seed and broccoli sprout blend (ERS92®) delivering GR and active myrosinase enzyme and was calculated to deliver at least the same dose of sulforaphane as in the prior randomized controlled trial in autism \[[@CR19], [@CR21]\]. In the prior randomized controlled trial, participants were provided pure sulforaphane in contrast to the current study, where sulforaphane was delivered as its precursor (GR) along with a conversion enzyme, myrosinase, which converts GR to sulforaphane in the body (providing the advantage of greater stability and a longer shelf life). Prior bioavailability studies suggest that the GR plus myrosinase is an excellent and efficient delivery method, but there is variability from person to person and the prior bioavailability studies were conducted in adults \[[@CR21]\]. At present, there have been no dose-efficacy trials, so it is unknown what an "optimal" dose might be. Dosing was adjusted in weight categories as follows: 32--41 kg (6 tablets = 222 μmol GR/day), 41--50 kg (7 tablets = 259 μmol GR/day), 50--59 kg (8 tablets = 296 μmol GR/day), 59--68 kg (9 tablets = 333 μmol GR/day), 68--77 kg (10 tablets = 370 μmol GR/day), 77--86 kg (12 tablets = 444 μmol GR/day), 86--95 kg (13 tablets = 481 μmol GR/day), and 95--105 kg (15 tablets = 555 μmol GR/day). Caregivers were advised to administer the tablets once a day in the morning. A simple grinding device ([www.carex.com/item/70071/Ultra-Pill-Crusher](http://www.carex.com/item/70071/Ultra-Pill-Crusher)) was provided to all families so that tablets could be ground and mixed into cold food (yogurt, applesauce, fruit juice or shakes, etc.), and most families provided tablets in this manner. All children completed baseline measures (described below) and provided urine samples during the same 2-week screening window, and then all children commenced treatment on the same day (January 21, 2016) (batch enrollment) and finished treatment on the same day (April 21, 2016).

Objectives and outcomes {#Sec5}
-----------------------

The primary goal of the study, defined a priori, was to determine if any observed changes in symptoms of ASD were correlated with changes in urinary metabolites. We hypothesized that sulforaphane treatment would lead to changes in markers of oxidative stress (or other physiological abnormalities) and that those changes would correlate with clinical improvements.

The two primary outcome measures were changes in behavior as measured by the Aberrant Behavior Checklist (ABC) and changes in social function as measured by the Social Responsiveness Scale (SRS); both scales are commonly used outcome measures in clinical trials of interventions in ASD. Parents/caregivers were asked to complete both measures at baseline, 4 weeks, and 12 weeks using an online and secure platform.

Urine was collected once during the 2-week window before treatment initiation and again at the end of the 12-week study period. Parents/caregivers were provided a sterile urine cup and were asked to collect a first morning urine (fasting since dinner the day before) and bring it immediately to their clinic visit, which was also arranged in the morning. Parents/caregivers were asked if the child had a medical illness at the time of urine collection, and no children had a current medical illness. Urine was immediately stored in 2-mL aliquots at − 80 °C. During the screening visit, children had a brief physical examination including height and weight to guide the proper dosing. Sulforaphane study tablets were provided at the screening visit along with dosing instructions. Parents were required to complete the intake forms online before the study coordinator contacted them to inform them to start taking the study supplement on January 21, 2016.

Safety assessments {#Sec6}
------------------

Parents/caregivers and teachers were advised to report any concerns about a new medical problem immediately to the study investigators, who were available at all times to receive reports of possible adverse effects. At the 4- and 12-week online questionnaires, parents/caregivers were asked to report any new medical problems or concerns for possible side effects.

Metabolomic analyses {#Sec7}
--------------------

All urine samples were sent on dry ice in one batch to Metabolon (Morrisville, NC). Metabolomics analysis was conducted at Metabolon as previously described \[[@CR22]\]. Briefly, samples were subjected to methanol extraction, then split into five aliquots for analysis by ultrahigh performance/mass spectrometry in the positive (two methods), negative or polar ion modes. Metabolites were identified by automated comparison of ion features to a reference library of chemical standards followed by visual inspection for quality control \[[@CR23]\]. For statistical analyses and data display, any missing values were assumed to be below the limits of detection; these values were imputed with the compound minimum (minimum value imputation). Data was then normalized by measured osmolality, which is necessary to reduce the variability in metabolomics analyses due to differing urine concentrations \[[@CR24]\]. A metabolic pathway for a given metabolite was assigned based on prior designations in the literature combined with experience from prior datasets at Metabolon.

Statistical methods {#Sec8}
-------------------

Summary statistics were used to describe the variables. Change in both the clinical variables and the metabolites was computed as post-test minus pre-test. Pearson's correlation coefficient was estimated and tested to index the association between the change in each of the two clinical scales and the change in each metabolite. Given the early-stage nature of the research, we did not adjust for multiple comparisons because we felt it was more important to risk a type II error than to miss a potentially important signal by being overly conservative, as has been suggested by prior authors \[[@CR25]\].

We defined, a priori, that a correlation cutoff of an absolute value of ≥ 0.6 was of potential clinical relevance, because, given our sample size of 15, we would have approximately 80% power to detect a correlation of that size and such a correlation accounts for roughly one third of the variance. Others have suggested that correlations with an absolute value of ≥ 0.6 indicate a moderate or higher correlation \[[@CR26]\] (and are hence of greatest interest in pointing to a mechanism of action).

We also examined the number of participants who had a clinical response, defined a priori as an improvement of four or more points in the ABC. We compared the pre-post changes in the ABC and SRS in the responder and non-responder groups using the Student's *t* test.

Results {#Sec9}
=======

Twenty-one of 35 students who were enrolled in the school completed the informed consent process for the study. Six families dropped out prior to completing any post-baseline information for the following reasons: two subjects withdrew consent prior to starting for unstated reasons; two subjects did not like the taste of the supplement; two parents filled out no surveys. The characteristics of the 15 children who provided follow-up information are shown in Table [1](#Tab1){ref-type="table"}. All children had a diagnosis of ASD, 80% were male, the mean age was 14.8, and there were no known genetic conditions among study participants. Their baseline ABC hyperactivity and irritability scores (Table [2](#Tab2){ref-type="table"}) are similar to those in the prior, seminal study of risperidone for behavioral problems in children with autism and "serious behavioral disturbances," where baseline hyperactivity and irritability scores were 31.8 (vs. 29.4 in the current study) and 26.2 (vs. 25.0 in the current study), respectively \[[@CR27]\].Table 1Characteristics of enrolled participantsCategoryCharacteristicSubjects (*N* = 15)%*N*GenderMale8012Female203EthnicityWhite609Asian/Pacific Islander71No response335Age7--1013211--1447715--21406Mean age14.7Primary diagnosisAutism spectrum disorder10015ComorbiditiesIntellectual disability406Language disorder274ADHD193Pica71Global Development Delay71Learning disability71Current medsSertraline132Lurasidone71Risperidone132Birth control132Zonisamide71*ADHD* attention deficit hyperactivity disorderTable 2Change in outcome scores over the 12-week study periodOutcome measureAdjusted mean scores (95% CI)Change from baseline (95% CI)Baseline1 month3 months1 month*p*3 months*p*Aberrant behavior checklist total score103.9 (72.0 to 135.9)94.2 (63.8 to 124.6)96.9 (65.7 to 128.0)− 9.7 (− 17.6 to − 1.8)0.02\*− 7.1 (− 17.4 to 3.2)0.18 Hyperactivity29.4 (21.1 to 37.8)27.7 (19.0 to 36.4)28.0 (20.1 to 35.8)− 1.7 (− 4.5 to 1.1)0.24− 1.5 (− 5.0 to 2.0)0.41 Irritability25.0 (12.9 to 37.1)22.2 (9.3 to 35.2)22.8 (10.1 to 35.5)− 2.8 (− 6.1 to 0.6)0.11− 2.2 (− 5.8 to 1.3)0.22 Inappropriateness5.3 (−0.4 to 10.9)5.0 (− 0.8 to 10.8)5.0 (−1.0 to 11.1)− 0.3 (− 0.8 to 0.3)0.35− 0.2 (− 1.3 to 0.9)0.72 Social withdrawal34.3 (22.8 to 45.7)30.7 (20.3 to 41.0)31.2 (19.8 to 42.7)− 3.6 (− 5.8 to − 1.4)0.001\*− 3.0 (− 5.6 to − 0.4)0.02\* Stereotypy9.9 (6.5 to 13.4)8.4 (4.9 to 11.8)9.8 (6.5 to 13.1)− 1.5 (− 2.8 to − 0.3)0.02\*− 0.09 (− 1.8 to 1.6)0.92Social responsiveness scale total score154.1 (106.6 to 201.7)147.0 (99.9 to 194.1)144.4 (95.5 to 193.3)− 7.1 (− 16.9 to 2.6)0.15−9.7 (− 18.7 to − 0.8)0.03\* Awareness22.2 (15.7 to 28.7)22.5 (16.2 to 28.7)22.7 (15.8 to 29.5)0.3 (− 0.9 to 1.4)0.650.5 (− 1.2 to 2.1)0.60 Cognition26.6 (15.3 to 37.9)25.4 (12.8 to 38.0)25.1 (14.0 to 36.3)− 1.2 (− 4.2 to 1.9)0.44− 1.5 (− 4.1 to 1.1)0.27 Communication55.6 (35.3 to 75.9)52.7 (32.8 to 72.7)50.6 (30.5 to 70.8)− 2.9 (− 6.5 to 0.8)0.13− 5.0 (− 8.4 to −1.5)0.005\* Mannerisms24.1 (19.1 to 29.1)22.7 (16.7 to 28.7)22.8 (17.3 to 28.3)− 1.5 (− 3.3 to 0.4)0.12− 1.3 (− 3.7 to 1.1)0.28 Motivation27.1 (17.5 to 36.8)24.6 (15.5 to 33.6)24.0 (13.6 to 34.3)− 2.6 (− 4.2 to − 0.9)0.003\*− 3.1 (− 5.1 to − 1.2)0.001\*Mean change scores were adjusted for age and gender\*Statistically significant change from baseline

Changes in symptoms {#Sec10}
-------------------

The change in ABC and SRS scores over the study period are shown in Table [2](#Tab2){ref-type="table"}. Mean scores on both measures showed improvements (decreases) over the 3-month study period, but only the change in the SRS was significant. The ABC improved − 7.1 points (95% CI − 17.4 to 3.2), and the SRS improved − 9.7 points (95% CI − 18.7 to − 0.8).

We also examined the number of participants who had a "clinical response," defined as an improvement in four or more points in the ABC. Eight participants had a clinical response compared to seven who were classified as non-responders. Responders exhibited a 21.8-point decrease (improvement) in total ABC (*p* \<  0.001) and a 20.2-point decrease in SRS (*p* \<  0.001), compared to increases of 10 points in ABC (*p* = 0.001) and 8 points in SRS (*p* = 0.076) for non-responders.

Figure [1](#Fig1){ref-type="fig"} demonstrates the marked improvement at 1-month for the ABC and a more gradual improvement from 1 to 3 months. The SRS demonstrates a slower initial improvement at 1 month with continued improvement to a significant change at 3 months.Fig. 1Change in mean outcome scores over time. **a** Change in mean aberrant behavior (ABC). **b** Change in mean social responsiveness (SRS). Mean scores were adjusted for sex and age of subjects. Decreasing score indicates clinical improvement

Parents were asked to provide subjective descriptions of the changes they noted in their children, and seven parents provided responses (Table [3](#Tab3){ref-type="table"}).Table 3Parental descriptions of behavior changeSubjectParental description1Increased conversation, asks questions, makes jokes, "more with us," decreased vocalizations2Engaging, more lucid, relaxed3More engaged, increased eye contact, more attentive, calmer4More flexibility5Less repetitive behavior, calmer, more language at school6Energy burst after taking supplement, difficult behavior if misses a dose, eager to try things, meltdowns improved (fewer, easier to "get out of," shorter duration)7Estimated 85% decrease in duration, frequency, and intensity of self-injurious behavior

Correlations between metabolite changes and clinical changes {#Sec11}
------------------------------------------------------------

The metabolite analysis measured 694 different urinary metabolites. Table [4](#Tab4){ref-type="table"} shows all urinary metabolites with correlations with an absolute value ≥ 0.6 with either the ABC or the SRS.Table 4Metabolite correlationsPrimary outcome measureMetaboliteABC\
Corr. *p* valueSRS\
Corr. *p* valueMetabolic pathwayAmino acids (endogenous) Arginine0.630.03Amino acid Assymetric dimethylarginine (ADMA)− 0.610.06Arginine catabolite (endogenous inhibitor of nitric oxide synthases) *N*-delta-acetylornithine0.620.06Arginine catabolite *N*-acetylputrescine− 0.650.04Arginine catabolite 4-Acetamidobutanoate− 0.620.06Arginine catabolite Tryptophan− 0.670.02Amino acid Tyrosine− 0.670.02Amino acid Theanine0.70.02a.a. deriv. from tea---of food origin Carnosine0.60.07a.a. deriv.; dietary; antioxidant; CNS functionality β-hydroxyisovalerate− 0.730.007a.a. metabolism (leucine) α-hydroxyisocaproate− 0.660.02a.a. metabolite (leucine) 4-Methyl-2-oxopentanoate− 0.620.06a.a. metabolite (leucine) α-hydroxyisovalerate− 0.60.04a.a. metabolism (isoleucine) 2-Methylbutyrylcarnitine (C5)0.60.07a.a. derived (isoleucine) 3-Hydroxyisobutyrate− 0.720.02a.a. metabolism (valine) *N*-carbamoylalanine0.730.01a.a. metabolite (alanine) *N*-methyltaurine− 0.630.05a.a. metabolite (cysteine) Taurine− 0.60.04a.a. metabolite (cysteine); critical for oxidative stress Dimethylglycine− 0.610.06a.a. metabolite (glycine) 1-Methylguanidine0.70.02a.a. metabolism *N*-acetylhistamine0.690.01a.a. metabolite (histidine)Amino acids (microbiome-associated or contributed) Tyramine O-sulfate0.610.03a.a. metabolite (tyrosine); catecholamine trigger 3-Indoxyl sulfate0.630.03a.a. metabolite (tryptophan); likely of gut microbiome origin 2-Oxindole-3-acetate0.610.06a.a. metabolite (tryptophan); likely of gut microbiome origin Indolin-2-one0.610.03a.a. metabolite (tryptophan); likely of gut microbiome origin Phenyllactate (PLA)− 0.610.06a.a. metabolite (phenylalanine), contribution from gut microbiome Phenylacetylglutamine0.650.02a.a. metabolite (glutamine); likely of gut microbiome origin Tryptophan betaine− 0.690.03a.a. (contribution from microbiome) *N*-acetyl-cadaverine0.650.02a.a. degradation product (lysine); likely of gut microbiome originBenzene metabolism Hydroquinone sulfate− 0.660.04Benzene metabolite; likely of exogenous originCaffeic acid derivatives Chlorogenate0.610.06Caffeic acid deriv.; dietary/food additiveCholesterol metabolism Cholesterol− 0.750.005Cholesterol Cholate− 0.730.02Cholesterol (bile acid) 12-Dehydrocholate− 0.690.03Cholesterol (bile acid), microbiome origin 7-Ketodeoxycholate− 0.60.07Cholesterol (bile acid), microbiome origin Glycocholenate sulfate− 0.86\< 0.001Cholesterol (bile acid), microbiome origin Cortisone− 0.80.002Cholesterol (hormone) Cortisol 21-glucuronide− 0.730.008Cholesterol (hormone) Epiandrosterone glucuronide− 0.680.01Cholesterol (hormone) 17α-hydroxypregnanolone glucuronide− 0.610.03Cholesterol (hormone) 5α-androstan-3β,17α-diol disulfate− 0.610.04Cholesterol (hormone) Pregnen-diol disulfate− 0.820.004Cholesterol (hormone) Dehydroepiandrosterone glucuronide− 0.780.008Cholesterol (hormone) 11-Ketoetiocholanolone sulfate− 0.760.01Cholesterol (hormone) 5α-pregnan-3β,20α-diol disulfate− 0.690.03Cholesterol (hormone) 5α-pregnan-3(α/β),20β-diol disulfate− 0.680.03Cholesterol (hormone) 21-Hydroxypregnenolone disulfate− 0.650.04Cholesterol (hormone) 3α,21-dihydroxy-5β-pregnane-11,20-dione 21-glucuronide− 0.610.06Cholesterol (hormone) Androstenediol 3β 17β d0− 0.60.07Cholesterol (hormone)Fatty acids Diglycerol0.660.02Lipid, likely of exogenous origin Pimelate (heptanedioate)0.610.030.610.06Dicarboxylate fatty acid (DFA) Suberate (octanedioate)0.750.01Dicarboxylate fatty acid (DFA) Azeloylcarnitine (C9-DC)0.660.02Acylcarnitine-conjugated DFAMicrobial polycyclic aromatic hydrocarbon (PAH) degradation Gentisate (2,5-diOH-benzoate)0.690.03Key intermediate in microbial PAH degradation 4-Hydroxybenzoate− 0.630.03Gut microbiome/amino acid 3-Ethylphenylsulfate− 0.630.03Gut microbiome/amino acidMonoterpene phenol Thymol sulfate0.620.03Monoterpene phenol of food originNeurotransmitters *N*-methylglutamate0.650.04Neurotransmitter Glutamine− 0.770.003Neurotransmitter Homovanillate (HVA)− 0.620.03− 0.650.04Neurotransmitter Hypoxanthine− 0.620.03− 0.640.05Neurotransmitter Serotonin−0.610.03NeurotransmitterOxidative stress γ-glutamylglutamine− 0.630.03Oxidative stress Methionine sulfone− 0.620.03Oxidative stressPolyol 3-Carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF)− 0.780.008Polyol associated with uremiaSphingomyelin Palmitoyl sphingomyelin (d18:1/16:0)− 0.690.01Sphingomyelin Stearoyl sphingomyelin (d18:1/18:0)− 0.770.004Sphingomyelin Lignoceroyl sphingomyelin (d18:1/24:0)− 0.740.006Sphingomyelin Behenoyl sphingomyelin (d18:1/22:0)− 0.740.006Sphingomyelin Sphingomyelin (d18:1/20:1, d18:2/20:0)− 0.760.004Sphingomyelin Sphingomyelin (d18:1/14:0, d16:1/16:0)− 0.750.005Sphingomyelin Sphingomyelin (d18:1/20:0, d16:1/22:0)− 0.740.006SphingomyelinSugars Arabinose− 0.70.02Sugar frequently associated with intestinal *Candida* overgrowthTCA cycle Malate− 0.650.02TCA cycle intermediateOther Gentisic acid-5-glucoside0.650.04Xenobiotic (chemical) Erythritol− 0.830.003Xenobiotic (diet-derived) 1-Palmitoyl-2-oleoyl-GPE (16:0/18:1)− 0.720.008Phospholipid*a.a* amino acid, *PAH* polycyclic aromatic hydrocarbon

Positive correlations indicate that, as the urinary metabolite increased, the ABC and SRS also increased (worsened). Negative correlations indicate that, as the urinary metabolite increased, the ABC and SRS decreased (improved). Metabolites that fall into similar, known metabolic pathways are highlighted and an interpretation is provided in the discussion.

Adverse events {#Sec12}
--------------

Six families reported that their child had a new medical event during the study period: one nausea and vomiting (but also associated with pica), one stomach flu, one inflammation in the esophagus and weight gain, one ruptured appendix, and one weight loss. The one serious adverse event (ruptured appendix) required hospitalization and surgery but led to no long-term complications. The committee on human research review determined that it was unlikely to be related to the study supplement.

Discussion {#Sec13}
==========

This study builds upon findings from one prior randomized, placebo-controlled trial, which found that the use of sulforaphane led to improvements in behavior and social responsiveness in children and young adults (aged 13--27) with ASD \[[@CR19]\]. Our primary goal was to examine changes in metabolites in children with ASD who were taking sulforaphane to determine a possible mechanism of action. We observed that a group of school-age children (mean age 14.8) showed a trend towards improvement in behavior (ABC) and a statistically significant improvement in social responsiveness after 12 weeks of treatment. The magnitude of improvements in the current study (− 9.7 points for the SRS and − 7.1 points for the ABC) were smaller than in the prior study (− 20.4 points for the SRS and − 21.4 points for the ABC), which may be related to the younger age of these participants or other differences in the study populations. One important difference in the study populations is that in the current study, all of the children were attending one specialized school with programs designed for children with ASD. The behavioral interventions in place at the school may have already been producing positive effects (at baseline) and limited the ability to detect further improvement from sulforaphane over the 12-week study (when compared to the prior study, where subjects were not in the same school).

In order to determine which metabolites might mediate clinical improvements, we examined correlations between the change in urinary metabolite levels and change in behavior and social responsiveness over the 12-week study. We defined, a priori, that a correlation with an absolute value of 0.6 or greater was potentially relevant and might indicate a mechanism of action. Of 694 measured urinary metabolites, 77 had correlations with an absolute value of ≥ 0.6. While it is not possible to discuss the implications of all of these correlations, several of these metabolite changes cluster into known pathways (Table [4](#Tab4){ref-type="table"}) that have been reported to be altered in children with ASD. These pathways involve metabolites involved in oxidative stress, amino acid/gut microbiome, neurotransmitters, hormones/stress response, and sphingomyelin metabolism, among others. Sulforaphane may affect these pathways through a variety of mechanisms including Nrf2-mediated induction of phase 2 detoxification enzymes, suppression of cytochrome P450 enzymes, induction of apoptotic pathways, and anti-inflammatory activity that have been described in detail \[[@CR28]\].

Many prior studies have found increased oxidative stress in children with ASD, which may be due to increased production or decreased clearance of reactive oxygen species (also known as ROS, or oxygen free-radicals). Children with ASD have been found to have lower levels of the metabolites that process oxygen free radicals (methionine, *S*-adenosylmethionine, homocysteine, cystathionine, cysteine, and total glutathione), higher levels of metabolites that are involved in the body's mechanism for reducing oxidative stress (oxidized glutathione, adenosine, and *S*-adenosylhomocysteine), and markers of protein and DNA oxidative damage \[[@CR3], [@CR29]\]. Also, two prior randomized controlled trials---one of the antioxidant NAC, and one of the methyl donor, methyl B12---have found that these treatments improve clinical symptoms in children with ASD \[[@CR17], [@CR18]\]. In the methyl B12 supplementation study, clinical improvements were correlated with increases in plasma methionine, decreases in *S*-adenosyl-homocysteine (SAH), and improvements in the ratio of *S*-adensylmethionine (SAM) to SAH \[[@CR18]\]. Interestingly, in the current study, clinical improvements were correlated with two metabolites known to be involved in redox metabolism. The negative correlations found with γ-glutamylglutamine and methionine sulfone indicate that, as the urinary levels of these metabolites increased, the symptoms scores decreased (improved). This suggests that sulforaphane may mediate beneficial clinical effects through increases in antioxidant capacity, which is one of its well-documented physiological effects \[[@CR20]\].

Abnormalities in amino acid metabolism have been reported in children with ASD compared to control children \[[@CR9], [@CR12], [@CR14], [@CR16]\], and this may be related to altered processing of amino acids by gut microbiota \[[@CR30]\]. We found correlations between clinical improvement and the amino acids tryptophan, tyrosine, and assymetric-dimethylarginine (ADMA, a derivative of the amino acid, arginine). The involvement of altered amino acids in the pathology of ASD is plausible since amino acids are building blocks for many key neurotransmitters and hormones, including catecholamines and serotonin \[[@CR30]\]. Six prior studies using urinary metabolomics noted increased urinary tryptophan in children with ASD \[[@CR7], [@CR9], [@CR12], [@CR14], [@CR16], [@CR30]\], and tryptophan is a key substrate in the serotonergic metabolic pathway. For tryptophan, tyrosine, and ADMA, the correlations in the current study were all negative, indicating that as the urinary levels of these amino acids increased, symptom scores decreased (improved). We also identified correlations between clinical improvement and changes in a number of other amino acids that are known to be associated with gut microbiota. Six of the eight metabolites in this category had positive correlations, indicating that decreased urinary levels were associated with improved clinical symptoms. It is not yet clear how sulforaphane may affect or improve the amino acid abnormalities (including those associated with the gut microbiome) and lead to clinical improvements.

We also found associations between clinical improvements and changes in five urinary neurotransmitter-related metabolites, including *N*-methylglutamate, glutamine, hypoxanthine, serotonin, and homovanillate (HMV), which is the normal end product of dopamine degradation and was elevated in the urine of children with ASD in a prior study \[[@CR14]\]. For all of the urinary neurotransmitters except *N*-methylglutamate, the correlations were negative, indicating that increases in the urinary levels of these metabolites were associated with lower scores on the ABC and SRS and therefore improved symptoms. This suggests that either increased production or increased elimination of these metabolites is correlated with beneficial effects. Hypoxanthine, which is part of the purine pathway, was previously found to be elevated in children with ASD \[[@CR9]\]. We also found that urinary glutamine was correlated with clinical improvements. Glutamatergic dysfunction has been hypothesized to be involved in the pathogenesis of ASD, with several studies reporting abnormal levels of glutamate in various regions in the brain \[[@CR13]\].

We found correlations between clinical improvements and a large number of hormones, some of them stress-related. Prior studies have found higher salivary stress hormones in children with ASD and higher hair cortisol levels, suggesting both acute and chronic elevation in stress hormones \[[@CR31], [@CR32]\]. Higher hair cortisol levels were associated with more severe autism symptoms and anxiety \[[@CR31]\]. In the current study, both cortisone and cortisol-21-glucuronide had negative correlations with ASD-related behavior, indicating that increased urinary levels were associated with improved symptoms. ASD behavior and social responsiveness were also related to a large number of other hormones, and all of these correlations were negative, again indicating that increased urinary levels of various hormones were associated with improved symptoms. It is not clear if this indicates that increased production or increased excretion is associated with improvement, but it highlights changes in hormonal function in ASD as an area for further study.

A novel finding of the current study is that improvement in behavior was correlated with seven different chemical forms of sphingomyelin. Seven sphingomyelin metabolites were each strongly negatively correlated with behavior, such that increased urinary levels were associated with improved behavior. Sphingomyelin is a sphingolipid found in animal cell membranes, especially in the membranous myelin sheath that surrounds nerve cells and axons. To our knowledge, there have been no prior reports of abnormalities in sphingolipid levels in children with ASD, but there are numerous studies documenting abnormalities in the size, number, and morphology of dendrites in autism, which is related to altered synapse function \[[@CR33]\]. Furthermore, sphingomyelin abnormalities have been noted in a number of other central nervous system disorders, including depression, anxiety, Alzheimer's disease, and amyotrophic lateral sclerosis, suggesting that it may have a central role in normal brain development and function \[[@CR34]--[@CR37]\]. It is not clear how sulforaphane might alter sphingomyelin metabolism or availability and whether this is related to clinical benefits, but if this association is confirmed, it has important clinical and treatment implications.

The current study has a number of limitations. Importantly, this was a pilot study to investigate whether metabolomics might be a useful tool to suggest pathways that may be involved in the mechanism of action of treatments (in this case, sulforaphane) in ASD. The study was open label and parent raters may have rated more positively knowing that their child was taking the sulforaphane, although the magnitude of benefit is lower than in the one prior randomized controlled trial. The ratings were also limited to the ABC and SRS to minimize respondent burden, and while these are widely used outcome tools in ASD, we did not include other measures of repetitive behavior or adaptive function, which might have shown clinical changes in other important areas. Many factors affect urinary metabolomics, including diet, environment, stress, sleep, age, and other factors. In the current study, the wide age range (7--21), different gender and pubertal state of subjects and the small sample size all limit the strength of the conclusions regarding urinary metabolomic changes. The variation in these environmental effects may have been minimized by having all the children attending the same school 5 days a week. However, the findings of this study should be viewed as hypothesis generating and should be confirmed in future studies with larger sample sizes. Future studies would also benefit from plasma biochemical assessments of antioxidant status pre- and post-treatment since this is likely a key pathway in the mechanism of action of sulforaphane. We found that change in the two outcome measures, ABC and SRS, were associated with mostly different metabolites. We believe this is to be expected since the measures assess different components of human behavior and are likely influenced by different metabolic pathways. Finally, we used a different delivery method of sulforaphane than in a prior randomized controlled trial in autism \[[@CR19]\] by providing a precursor, glucoraphanin, along with a conversion enzyme, myrosinase. Although the dosing was designed to produce a similar level of sulforaphane, it is possible that differences in bioavailable sulforaphane levels between the two studies could have led to differences in clinical results.

Conclusions {#Sec14}
===========

We are not aware of any prior studies that have examined changes in urinary metabolites during a clinical trial of a treatment for autism. In this pilot study, we demonstrated the feasibility of using metabolomics to identify urinary metabolites that are correlated with clinical improvements and might therefore represent a mechanism of action. One group of metabolites in particular, the sphingolipid/sphingomyelin group, was highlighted as being significantly associated with improvement. Other urinary metabolite changes that were correlated with clinical improvement are related to oxidative stress, amino acid metabolism/gut microbiome metabolites, neurotransmitters, stress, and other hormones. These findings suggest that urinary metabolomics may be a tool to identify important changes in the quest to determine how certain biological interventions work to reduce specific symptoms of ASD. This may further provide clues to the underlying, active pathophysiology of ASD and may allow for more precise interventions targeted to the unique metabolome of each individual with this disorder.
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